D. Knight

发表

Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine.

C. Nemeroff, M. Owens, D. Knight, 2001, Biological psychiatry.

Release of corticotropin-releasing factor from rat brain regions in vitro.

C. Nemeroff, M. Smith, D. Knight, 1986, Endocrinology.

Apolipoprotein E epsilon 4.

C. Nemeroff, W. McDonald, L. Tupler, 1994, Neurology.

Apolipoprotein E ε4

C. Nemeroff, W. McDonald, L. Tupler, 1994, Neurology.

Is There a Relationship between Baseline and Treatment-Associated Changes in [3H]-IMI Platelet Binding and Clinical Response in Major Depression?

C. Nemeroff, G. Tollefson, D. Knight, 1996, Neuropsychopharmacology.

Chronic Administration of the Triazolobenzodiazepine Alprazolam Produces Opposite Effects on Corticotropin-Releasing Factor and Urocortin Neuronal Systems

C. Nemeroff, M. Owens, D. Knight, 2000, The Journal of Neuroscience.

The effects of alprazolam on corticotropin-releasing factor neurons in the rat brain: acute time course, chronic treatment and abrupt withdrawal.

C. Nemeroff, M. Owens, D. Knight, 1991, The Journal of pharmacology and experimental therapeutics.

Further studies on platelet serotonin transporter binding in depression.

K. Krishnan, C. Nemeroff, W. E. Craighead, 1994, The American journal of psychiatry.

Marked reduction in the number of platelet-tritiated imipramine binding sites in geriatric depression.

C. Nemeroff, D. Blazer, D. Knight, 1988, Archives of general psychiatry.

N-oxides of phenothiazine antipsychotics: effects on in vivo and in vitro estimates of dopaminergic function.

R. Mailman, C. Kilts, D. Knight, 1983, The Journal of pharmacology and experimental therapeutics.

Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine

C. Nemeroff, M. Owens, D. Knight, 2001, Biological Psychiatry.

Effects of Sodium Valproate on Corticotropin-Releasing Factor Systems in Rat Brain

C. Nemeroff, M. Owens, D. Knight, 2001, Neuropsychopharmacology.

Apolipoprotein E-ε4 frequency in geriatric depression

K. Krishnan, C. Nemeroff, B. Carroll, 1996, Biological Psychiatry.

Elevated plasma concentrations of alpha 1-acid glycoprotein, a putative endogenous inhibitor of the tritiated imipramine binding site, in depressed patients.

K. Krishnan, C. Nemeroff, D. Knight, 1990, Archives of general psychiatry.

Effects of thioridazine and its metabolites on dopaminergic function: drug metabolism as a determinant of the antidopaminergic actions of thioridazine.

R. Mailman, C. Kilts, G. Breese, 1984, The Journal of pharmacology and experimental therapeutics.

Reduced platelet tritium-labeled imipramine binding sites in women with premenstrual syndrome.

C. Nemeroff, D. Knight, J. Steege, 1992, American journal of obstetrics and gynecology.

The simultaneous determination of neurotensin and its major fragments by on-line trace enrichment HPLC with electrochemical detection.

C. Kilts, C. Nemeroff, D. Knight, 1996, Life sciences.

Preclinical evaluation of the putative antidepressant nefazodone

C. Nemeroff, M. Owens, D. Knight, 1993 .

Paroxetine binding to the rat norepinephrine transporter in vivo

C. Nemeroff, M. Owens, D. Knight, 2000, Biological Psychiatry.

The 5-hydroxytryptamine2 agonist, (+-)-1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane stimulates the hypothalamic-pituitary-adrenal (HPA) axis. I. Acute effects on HPA axis activity and corticotropin-releasing factor-containing neurons in the rat brain.

C. Nemeroff, M. Owens, D. Knight, 1991, The Journal of pharmacology and experimental therapeutics.

Alterations in the hypothalamic-pituitary-adrenal axis in a proposed animal model of depression with genetic muscarinic supersensitivity.

D. Overstreet, C. Nemeroff, M. Owens, 1991, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

The 5-hydroxytryptamine2 agonist, (+-)-1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane stimulates the hypothalamic-pituitary-adrenal (HPA) axis. II. Biochemical and physiological evidence for the development of tolerance after chronic administration.

C. Nemeroff, M. Owens, D. Knight, 1991, The Journal of pharmacology and experimental therapeutics.

SOMATOSTATIN: A NEUROPEPTIDE SYSTEM PATHOLOGICALLY ALTERED IN ALZHEIMER'S DISEASE AND DEPRESSION

C. Nemeroff, D. Knight, G. Bissette, 1992, Clinical neuropharmacology.

Alterations in platelet serotonin transporter binding in women with postpartum onset major depression.

C. Nemeroff, M. Owens, D. Knight, 2004, Journal of psychiatric research.

Platelet [3H]-imipramine binding and leukoencephalopathy in geriatric depression

Mustafa M. Husain, Orest B. Boyko, William W. McDonald, 1991, Biological Psychiatry.

Is decreased imipramine binding by platelet membranes in major depression associated with plasma autoantibodies to imipramine binding sites?

C. Nemeroff, D. Knight, J. Peter, 1990, Biological Psychiatry.

Reduced inhibitory effect of imipramine on radiolabeled serotonin uptake into platelets in geriatric depression

K. Krishnan, C. Nemeroff, D. Blazer, 1989, Biological Psychiatry.

Apolipoprotein E-epsilon 4 frequency in geriatric depression.

K. Krishnan, C. Nemeroff, B. Carroll, 1996, Biological psychiatry.

The serotonergic antidepressant nefazodone inhibits the serotonin transporter: in vivo and ex vivo studies.

M. Owens, D. Knight, Charles B. Nemeroff, 1995, Life sciences.

Platelet 5-hydroxytryptamine (5-HT) transporter and 5-HT2A receptor binding after chronic hypercorticosteronemia, (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane administration or neurotoxin-induced depletion of central nervous system 5-HT in the rat.

C. Nemeroff, M. Owens, D. Knight, 1996, The Journal of pharmacology and experimental therapeutics.